|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Tight junctions in inflammatory bowel diseases and inflammatory bowel disease associated colorectal cancer显示文摘Inflammatory bowel diseases are characterised by inflammation that compromises the integrity of the epithelial barrier. The intestinal epithelium is not only a static barrier but has evolved complex mechanisms to control and regulate bacterial interactions with the mucosal surface. Apical tight junction proteins are critical in the maintenance of epithelial barrier function and control of paracellular permeability. The characterisation of alterations in tight junction proteins as key players in epithelial barrier function in inflammatory bowel diseases is rapidly enhancing our understanding of critical mechanisms in disease pathogenesis as well as novel therapeutic opportunities. Here we give an overview of recent literature focusing on the role of tight junction proteins, in particular claudins, in inflammatory bowel diseases and inflammatory bowel disease associated colorectal cancer. | Jonathan Landy Emma Ronde Nick English Sue K Clark Ailsa L Hart Stella C Knight Paul J Ciclitira Hafid Omar Al-Hassi | 2016 | World Journal of Gastroenterology2016，22，11： | 39 |
| 2 | Golgi protein-73:A biomarker for assessing cirrhosis and prognosis of liver disease patients显示文摘BACKGROUND Reliable biomarkers of cirrhosis,hepatocellular carcinoma(HCC),or progression of chronic liver diseases are missing.In this context,Golgi protein-73(GP73)also called Golgi phosphoprotein-2,was originally defined as a resident Golgi type II transmembrane protein expressed in epithelial cells.As a result,GP73 expression was found primarily in biliary epithelial cells,with only slight detection in hepatocytes.However,in patients with acute or chronic liver diseases and especially in HCC,the expression of GP73 is significantly up-regulated in hepatocytes.So far,few studies have assessed GP73 as a diagnostic or prognostic marker of liver fibrosis and disease progression.AIM To assess serum GP73 efficacy as a diagnostic marker of cirrhosis and/or HCC or as predictor of liver disease progression.METHODS GP73 serum levels were retrospectively determined by a novel GP73 ELISA(QUANTA Lite®GP73,Inova Diagnostics,Inc.,Research Use Only)in a large cohort of 632 consecutive patients with chronic viral and non-viral liver diseases collected from two tertiary Academic centers in Larissa,Greece(n=366)and Debrecen,Hungary(n=266).Aspartate aminotransferase(AST)/Platelets(PLT)ratio index(APRI)was also calculated at the relevant time points in all patients.Two hundred and three patients had chronic hepatitis B,183 chronic hepatitis C,198 alcoholic liver disease,28 autoimmune cholestatic liver diseases,15 autoimmune hepatitis,and 5 with other liver-related disorders.The duration of follow-up was 50(57)mo[median(interquartile range)].The development of cirrhosis,liver decompensation and/or HCC during follow-up were assessed according to internationally accepted guidelines.In particular,the surveillance for the development of HCC was performed regularly with ultrasound imaging and alpha-fetoprotein(AFP)determination every 6 mo in cirrhotic and every 12 mo in non-cirrhotic patients.RESULTS Increased serum levels of GP73(>20 units)were detected at initial evaluation in 277 out of 632 patients(43.8%).GP73-seropositivity correlated at baseline with the presence of cirrhosis(96.4%vs 51.5%,P<0.001),decompensation of cirrhosis(60.3%vs 35.5%,P<0.001),presence of HCC(18.4%vs 7.9%,P<0.001)and advanced HCC stage(52.9%vs 14.8%,P=0.002).GP73 had higher diagnostic accuracy for the presence of cirrhosis compared to APRI score[Area under the curve(AUC)(95%CI):0.909(0.885-0.934)vs 0.849(0.813-0.886),P=0.003].Combination of GP73 with APRI improved further the accuracy(AUC:0.925)compared to GP73(AUC:0.909,P=0.005)or APRI alone(AUC:0.849,P<0.001).GP73 levels were significantly higher in HCC patients compared to non-HCC[22.5(29.2)vs 16(20.3)units,P<0.001)and positively associated with BCLC stage[stage 0:13.9(10.8);stage A:17.1(16.8);stage B:19.6(22.3);stage C:32.2(30.8);stage D:45.3(86.6)units,P<0.001]and tumor dimensions[very early:13.9(10.8);intermediate:19.6(18.4);advanced:29.1(33.6)units,P=0.004].However,the discriminative ability for HCC diagnosis was relatively low[AUC(95%CI):0.623(0.570-0.675)].Kaplan-Meier analysis showed that the detection of GP73 in patients with compensated cirrhosis at baseline,was prognostic of higher rates of decompensation(P=0.036),HCC development(P=0.08),and liver-related deaths(P<0.001)during follow-up.CONCLUSION GP73 alone appears efficient for detecting cirrhosis and superior to APRI determination.In combination with APRI,its diagnostic performance can be further improved.Most importantly,the simple GP73 measurement proved promising for predicting a worse outcome of patients with both viral and nonviral chronic liver diseases. | Nikolaos K Gatselis Tamás Tornai Zakera Shums Kalliopi Zachou Asterios Saitis Stella Gabeta Roger Albesa Gary L Norman Mária Papp George N Dalekos | 2020 | World Journal of Gastroenterology2020，26，34： | 21 |
| 3 | Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: A hidden threat显示文摘AIM: To present the characteristics and the course of a series of anti- hepatitis B virus core antibody (HBc) antibody positive patients, who experienced hepatitis B virus (HBV) reactivation after immunosuppression. METHODS: We retrospectively evaluated in our tertiary centers the medical records of hepatitis B virus surface antigen (HBsAg) negative patients who suffered from HBV reactivation after chemotherapy or immunosuppression during a 3-year period (2009-2011). Accordingly, the clinical, laboratory and virological characteristics of 10 anti-HBc (+) anti-HBs (-)/HBsAg (-) and 4 anti-HBc (+)/antiHBs (+)/HBsAg (-) patients, who developed HBV reactivation after the initiation of chemotherapy or immunosuppressive treatment were analyzed. Quantitative determination of HBV DNA during reactivation was performed in all cases by a quantitative real time polymerase chain reaction kit (COBAS Taqman HBV Test; cut-off of detection: 6 IU/mL). RESULTS: Twelve out of 14 patients were males; median age 74.5 years. In 71.4% of them the primary diagnosis was hematologic malignancy; 78.6% had received rituximab (R) as part of the immunosuppressive regimen. The median time from last chemotherapy schedule till HBV reactivation for 10 out of 11 patients who received R was 3 (range 2-17) mo. Three patients (21.4%) deteriorated, manifesting ascites and hepatic encephalopathy and 2 (14.3%) of them died due to liver failure. CONCLUSION: HBsAg-negative anti-HBc antibody positive patients can develop HBV reactivation even 2 years after stopping immunosuppression, whereas prompt antiviral treatment on diagnosis of reactivation can be lifesaving. | Kalliopi Zachou Alexandros Sarantopoulos Nikolaos K Gatselis Themistoklis Vassiliadis Stella Gabeta Aggelos Stefos Asterios Saitis Panagiota Boura George N Dalekos | 2013 | World Journal of Hepatology2013，5，7： | 6 |
| 4 | Primary biliary cirrhosis-specific autoantibodies in first degree relatives of Greek primary biliary cirrhosis patients显示文摘AIM:To determine the prevalence and significance of primary biliary cirrhosis (PBC)-specific autoantibodies in firstdegree relatives (FDRs) of Greek PBC patients. METHODS:The presence of antimitochondrial antibodies (AMA) and PBCspecific antinuclear antibodies (ANA) were determined using indirect immunofluores-cence assays, dot-blot assays, and molecularly based enzyme-linked immunosorbent assays in 101 asymp-tomatic for liver-related symptoms FDRs of 44 PBCpatients. In order to specify our results, the same investigation was performed in 40 healthy controls and in a disease control group consisting of 40 asymptomatic for liver-related symptoms FDRs of patients with other autoimmune liver diseases namely, autoimmune hepati-tis-1 or primary sclerosing cholangitis (AIH-1/PSC). RESULTS: AMA positivity was observed in 19 (only 4 with abnormal liver function tests) FDRs of PBC patients and none of the healthy controls. The preva-lence of AMA was significantly higher in FDRs of PBC patients than in AIH-1/PSC FDRs and healthy controls [18.8%, 95% confidence interval (CI):12%-28.1% vs 2.5%, 95% CI:0.1%-14.7%, P = 0.01; 18.8%, 95% CI:12%-28.1% vs 0%, 95% CI: 0%-10.9%, P = 0.003, respectively]. PBC-specific ANA positivity was observed in only one FDR from a PSC patient. Multivariate analysis showed that having a proband with PBC independently associated with AMA positivity (odds ratio: 11.24, 95% CI:1.27-25.34, P = 0.03) whereas among the investigated comorbidities and risk factors, a positive past history for urinary tract infections (UTI) was also independently associated with AMA detection in FDRs of PBC patients (odds ratio:3.92, 95% CI:1.25-12.35,P = 0.02). CONCLUSION:In FDRs of Greek PBC patients, AMA prevalence is significantly increased and independently associated with past UTI. PBC-specific ANA were not detected in anyone of PBC FDRs. | Theodoros A Zografos Nikolaos Gatselis Kalliopi Zachou Christos Liaskos Stella Gabeta George K Koukoulis George N Dalekos | 2012 | World Journal of Gastroenterology2012，18，34： | 4 |
| 5 | Prodrug strategies to overcome poor water solubility 显示文摘 | STELLA V J NTI-ADDAE K W | 2007 | Adv Drug Deliv Rev2007，59，7： | 1 |
| 6 | Preoperative investigations for metastatic staging of colon and rectal cancer across multiple centres- what is current practice显示文摘 | Kosmider S Stella DL Field K | 2009 | Colorectal Dis2009，11，6： | 1 |
| 7 | Three-dimensional imaging for virtual assessment and treatment simulation in orthognathic sur- gery 显示文摘 | Caloss R Atkins K Stella J P | 2007 | Oral Maxillofac Surg Clin N Am2007，19，3： | 1 |
| 8 | Papillary muscle rupture following percutaneous mitral valvuloplasty显示文摘 | Onsea K Chamuleau S Stella P | | 0，，3： | 1 |
| 9 | Prodrugs and site-specific drug delivery 显示文摘 | STELLA V J HIMMELSTEIN K J | 1980 | JMedChem1980，23，12： | 1 |
| 10 | Molecular simulation of adsorption natural gas显示文摘 | MATRANGA K R STELLA A MYERS A L | 1992 | Separation Science and Technology1992，27，14： | 1 |
| 11 | Prodrug strategies to overcome poor water solubility显示文摘 | Stella V J Nti-Addae K W | 2007 | Advanced Drug Delivery Reviews2007，59，7： | 1 |
| 12 | NO2 vertical profiles retrieved from ground-based measurements during spring 1999 in the canadian Arctic 显示文摘 | Stella M L Melo Farahani E Strong K | 2004 | Advances in Space Research2004，34，： | 1 |
| 13 | Prodrug strategies to overcome poor water solubility显示文摘 | Stella V J Nti-Addae K W | 2007 | Adv Drug Deliver Rev2007，59，7： | 1 |
| 14 | A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2显示文摘 | Sidera K Gaitanou M Stellas D | 2008 | J Biol Chem2008，283，： | 1 |
| 15 | Release of testosterone from an osmotic pump tablet utilizing (SBE)7m-β-CD as both a solubilier and osmotic pump agent显示文摘 | Okimoto K Rajewski RA Stella VJ | 1999 | J Controlled Release1999，58，： | 1 |
| 16 | Release of testosterone from an osmotic pump tablet utilizing (SBE)7m - β - cyclodextrin as both a solubilizing and an osmotic pump agent 显示文摘 | Okimoto K Rajewski R A Stella V J | 1999 | J Control Release1999，58，1： | 1 |
| 17 | A fuzzy varia- ble structure controller for STATCOM显示文摘 | STELLA MORRIS DASH P K BASU K P | 2003 | Electric Power System Research2003，，65： | 1 |
| 18 | A High quality draft consensus sequence of the genome of a heterozygous grapevine variety显示文摘 | VELASCO R ZHARKIKH A TROGGIO M CARTWRIGHT DA CESTARO A PRUSS D PINDO M FITZGERALD LM VEZZULLI S REID J MALACARNE G ILIEV D COPPOLA G WARDELL B MICHELETTI D MACALMA T FACCI M MITCHELL JT PERAZZOLLI M ELDREDGE G GATTO P OYZERSKI R MORETTO M GUTIN N STEFANINI M CHEN Y SEGALA C DAVENPORT C DEMATYTE L MRAZ A BAT- TILANA J STORMO K COSTA F TAO Q SI-AMMOUR A HARKINS T LACKEY A PERBOST C TAILLON B STELLA A SOLOVYEV V FAWCETY JA STERCK L VANDEPOELE K GRANDO SM TOPPO S MOSER C LANCHBURY J BOGDEN R SKOLNICK M SGARAMELLA V BHATNAGAR SK FONTANA P GUTIN A VAN DE PEER Y SALAMINI F VIOLA R | 2007 | PLoS One2007，2，： | 1 |
| 19 | A critical role for HSP90 in cancer cell invasion involves interactionwith the extracellular domain of HER-2显示文摘 | Sidera K Gaitanou M Stellas D | 2008 | J Biol Chem2008，283，4： | 1 |
| 20 | Re-sults from Kenya’s 2014 report card on physical activity andbody weight of children and youth 显示文摘 | LUCY-JOY M WACHIRA STELLA K MUTHURI^/a/ | 2014 | J Phys Act Health2014，11，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员